CBDP (Cannabidiphorol) is a newly discovered cannabinoid that was identified in 2019 from a medical cannabis plant. It has similar structure to the well-known CBD, however CBDP possesses a longer hydrocarbon chain which can produce different effects on the body. CBDP has potential anti-anxiety, anti-stress, and pain-relieving capabilities, as well as being non-psychoactive. It has been studied for its therapeutic effects and may become an important part of medical cannabis treatments in the future.

Strongest Cannabinoid

Natural Found

Medical Potential

CBDP Health Benefits

Cannabidiphorol (CBDp) is a phytocannabinoid found in the Cannabis sativa plant. It has been studied for its potential therapeutic benefits, including anti-inflammatory, antioxidant, anti-anxiety, and anti-seizure properties. Unlike THC, CBDp does not produce any psychoactive effects. Research has shown that CBDp may be effective in treating a variety of medical conditions such as epilepsy, anxiety, chronic pain, and depression. Additional studies are needed to fully understand the potential therapeutic benefits of CBDp.

How strong is CBD-P compared


First of all, it is very difficult to measure the strength of a substance because its effect is relatively different for everyone. What is a good measure of strength is how strongly the cannabinoid binds to the receptors. Since we could not find any scientific data on the strength of CBD-P, we will try to measure the strength of CBD-P. Let’s take a study that measured the strength of different THC derivatives including THC-P.


33x stronger?

Binding affinity at human CB1 and CB2 receptors

THCP resulted 33-times more active than (-)-trans-Δ9-THC (Ki = 40 nM), 63-times more active than (-)-trans-Δ9-THCV (Ki = 75.4 nM) and 13-times more active than the newly discovered (-)-trans-Δ9-THCB (Ki = 15 nM) against CB1 receptor12,14. Moreover, the new identified (-)-trans-Δ9-THCP resulted about 5- to 10-times more active against CB2 receptor (Ki = 6.2 nM), in contrast with (-)-trans-Δ9-THC, (-)-trans-Δ9-THCB and (-)-trans-Δ9-THCV, which instead showed a comparable binding affinity.

CBD-P Risk?

Need to know more?